BACKGROUND: Long-term treatment of cardiac transplant recipients with cyclosporine results in a progressive decline in kidney function in a large number of patients. This complication is one of the most important prognostic parameters that determine the outcome of cardiac transplantation. Transforming growth factor-beta (TGF-beta) is one of the most potent mediators of the fibrogenic effects of cyclosporine. METHODS AND RESULTS: With the use of an experimental rodent model, heterotopic heart transplantation was performed, creating histocompatibility-disparate allografts. Because TGF-beta in part mediates both the immunosuppressive and nephrotoxic effects of cyclosporine, recipients were treated with cyclosporine with and without anti-TGF-beta antibody to determine whether anti-TGF-beta antibody could reduce the nephrotoxic effects of cyclosporine. Intrarenal expression of TGF-beta, collagen, fibronectin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-2 was studied with the use of reverse transcription-polymerase chain reaction. Intrarenal expression of TGF-beta protein was studied by immunohistochemistry and with the use of ELISA to quantify circulating levels of TGF-beta protein in plasma. Cyclosporine-induced graft survival (immunosuppressive effect) was abrogated with a higher concentration (2.5 mg/kg) of anti-TGF-beta antibody, whereas a lower concentration (1 mg/kg) inhibited both cyclosporine-induced expression of fibrogenic molecules and renal toxicity. CONCLUSIONS: These results provide credence to the pivotal role of TGF-beta in immunosuppression-associated renal toxicity in recipients of cardiac transplantation. Furthermore, these findings support a potentially significant therapeutic use of optimal concentration of anti-TGF-beta antibody to ameliorate cyclosporine-associated nephrotoxicity in cardiac transplant recipients.
BACKGROUND: Long-term treatment of cardiac transplant recipients with cyclosporine results in a progressive decline in kidney function in a large number of patients. This complication is one of the most important prognostic parameters that determine the outcome of cardiac transplantation. Transforming growth factor-beta (TGF-beta) is one of the most potent mediators of the fibrogenic effects of cyclosporine. METHODS AND RESULTS: With the use of an experimental rodent model, heterotopic heart transplantation was performed, creating histocompatibility-disparate allografts. Because TGF-beta in part mediates both the immunosuppressive and nephrotoxic effects of cyclosporine, recipients were treated with cyclosporine with and without anti-TGF-beta antibody to determine whether anti-TGF-beta antibody could reduce the nephrotoxic effects of cyclosporine. Intrarenal expression of TGF-beta, collagen, fibronectin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-2 was studied with the use of reverse transcription-polymerase chain reaction. Intrarenal expression of TGF-beta protein was studied by immunohistochemistry and with the use of ELISA to quantify circulating levels of TGF-beta protein in plasma. Cyclosporine-induced graft survival (immunosuppressive effect) was abrogated with a higher concentration (2.5 mg/kg) of anti-TGF-beta antibody, whereas a lower concentration (1 mg/kg) inhibited both cyclosporine-induced expression of fibrogenic molecules and renal toxicity. CONCLUSIONS: These results provide credence to the pivotal role of TGF-beta in immunosuppression-associated renal toxicity in recipients of cardiac transplantation. Furthermore, these findings support a potentially significant therapeutic use of optimal concentration of anti-TGF-beta antibody to ameliorate cyclosporine-associated nephrotoxicity in cardiac transplant recipients.
Authors: James Voelker; Paul H Berg; Matthew Sheetz; Kevin Duffin; Tong Shen; Brian Moser; Tom Greene; Samuel S Blumenthal; Ivan Rychlik; Yoram Yagil; Philippe Zaoui; Julia B Lewis Journal: J Am Soc Nephrol Date: 2016-09-19 Impact factor: 10.121
Authors: Kelly A Harradine; Katie Ridd; Elise F Saunier; Frederic F Clermont; Jesus Perez-Losada; Dan H Moore; Ervin H Epstein; Boris C Bastian; Rosemary J Akhurst Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: Galen M Pieper; Vani Nilakantan; Thanh K Nguyen; Gail Hilton; Allan M Roza; Christopher P Johnson Journal: Antioxid Redox Signal Date: 2008-06 Impact factor: 8.401
Authors: Galen M Pieper; Irina A Ionova; Brian C Cooley; Raymond Q Migrino; Ashwani K Khanna; Jennifer Whitsett; Jeannette Vásquez-Vivar Journal: J Pharmacol Exp Ther Date: 2009-03-23 Impact factor: 4.030
Authors: Swati Biswas; Jeffry S Nyman; JoAnn Alvarez; Anwesa Chakrabarti; Austin Ayres; Julie Sterling; James Edwards; Tapasi Rana; Rachelle Johnson; Daniel S Perrien; Scott Lonning; Yu Shyr; Lynn M Matrisian; Gregory R Mundy Journal: PLoS One Date: 2011-11-11 Impact factor: 3.240